Clinical trials
Metastatic Colorectal Cancer clinical trials
Below are recruiting metastatic colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Birmingham, AlabamaAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT06792695RecruitingPhase 2
Study of new treatments for colorectal cancer
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Scottsdale, ArizonaAges 18–130 - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT05008809RecruitingPhase 3
FIRE-9 trial: chemo after colon cancer metastasis removal
This trial studies whether giving chemotherapy after surgery or ablation (destroying spots of cancer) can improve outcomes in people with metastatic colon or rectal cancer. It compares post-treatment chemotherapy strategies to reduce the chance the cancer comes back.
AmbergAges 18 years+ - NCT05068531Recruiting
Detecting early treatment failure in stage IV colon cancer
This study looks for early signs that treatment is not working in people with stage IV colon or rectal cancer that has spread only to the liver. It may help doctors adjust care sooner by using regular blood, stool, and tissue samples around liver procedures.
Montreal, QuebecAges 18 years+ - NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05232409RecruitingPhase 1
Zeaxanthin in metastatic cancer, alone or with pembrolizumab
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Paramus, New JerseyAges 18–99 - NCT05240950RecruitingPhase 1
CAR-T cell therapy for colorectal cancer in the liver
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT05314400Recruiting
MRI with contrast for metastatic colon cancer liver lesions
This trial studies an MRI technique using a contrast dye (gadopetate/gadolinium) to better look at liver lesions that may be colon cancer spread. It may help doctors more accurately assess which liver tumors are present and guide next steps.
London, OntarioAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT05427487RecruitingPhase 1
Testing a medicine injected into tumors for advanced cancers
This Phase 1 study tests IVX037, a medicine given directly into a solid tumor, to see if it is safe and may shrink tumors. It is for people with certain advanced colorectal, stomach/gastroesophageal, or ovarian cancers that have limited treatment options.
Sydney, New South WalesAges 18–85 - NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT05462236RecruitingPhase 2
Study drug AUM001 with immunotherapy or chemotherapy for metastatic colon cancer
This Phase 2 trial tests AUM001 (a targeted drug) combined with either pembrolizumab (an immunotherapy) or irinotecan (a chemotherapy) in people with metastatic colorectal cancer. It aims to shrink tumors and improve outcomes when standard treatments have already been tried.
Camperdown, New South WalesAges 18 years+ - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT05611034RecruitingPhase 1
Testing a lung treatment for colorectal cancer spread to lungs
This Phase 1 trial tests a targeted treatment delivered to the lungs for colorectal cancer that has spread to the lungs. It aims to see if the approach is safe and can reach lung tumors, especially when there are multiple lung lesions.
Toronto, OntarioAges 18–70 - NCT05639413Recruiting
Study of biology in people with BRAF V600E metastatic colon cancer
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
AvignonAges 18 years+ - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Irvine, CaliforniaAges 18 years+ - NCT05725200RecruitingPhase 2
Personalized treatment plan for metastatic colon or rectal cancer
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
OsloAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic colorectal cancer?
- Yes. Clin2 currently lists 540 recruiting metastatic colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Colorectal Cancer (CRC)
- Metastatic Colorectal Cancer (mCRC)
- Unresectable Metastatic Colorectal Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Refractory Metastatic Colorectal Cancer
- MSS Metastatic Colorectal Cancer
- Microsatellite Stable Metastatic Colorectal Cancer
- Non-metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.